
Claims


1. Use of a compound represented by general structure (V**I**):




(**VI**)

wherein,

- T is represented by structure (**IIIa**) or (**IIIb**):



(**IIIa**)



(**IIIb**)

wherein each R^7 is methyl;

- N* is $–NR^3$ or $–N^+R^3R^4$ X–;
- R^3 is selected from hydrogen (H), C_1 – C_6 alkyl or C_1 – C_6 alkenyl, wherein the alkyl or alkenyl moiety may be substituted with one or more halogen atoms, hydroxyl moieties or (halo)alkoxy moieties, or R^3 is absent when N* is part of an imine moiety; or optionally R^3 is joined with a backbone atom of the linker L in a cyclic structure; and
- R^4 is selected from hydrogen (H) or C_1 – C_6 alkyl, wherein the alkyl moiety may be substituted with one or more halogen atoms or (halo)alkoxy moieties;
- X is an anion, preferably a pharmaceutically acceptable anion,

in the manufacture of a medicament for treating, preventing or suppressing symptoms associated with at least one of:

a) depression; and,

b) headache and/or migraine.

2. The use according to claim 1, wherein the medicament eliminates, reduces the severity of, and/or reduces the frequency of occurrence of at least one symptom of the depression, preferably as determined using the Beck Depression Index.

3. The use according to any one of claims 1 – 2, wherein the symptom of the depression includes at least one of apathy, persistent feelings of sadness, feelings of hopelessness or helplessness, having low self-esteem, feeling inadequate, excessive guilt, feelings of wanting to die, loss of interest in usual activities or activities once enjoyed, difficulty with relationships, sleep disturbances, changes in appetite or weight, decreased energy, difficulty concentrating, a decrease in the ability to make decisions, suicidal thoughts or attempts, frequent physical complaints, running away or threats of running away from home, hypersensitivity to failure or rejection, irritability, hostility, or aggression.

4. The use according to any one of claims 1 – 3, wherein an additional active agent selected from the group consisting of a norepinephrine reuptake inhibitor, a selective serotonin reuptake inhibitor, a tricyclic antidepressant, a monoamine oxidase inhibitor, and combinations thereof, is to be further administered.

5. The use according to claim 1, wherein the headache comprises tension-type headaches or wherein the migraine comprises common migraine, classic migraine, familial hemiplegic migraine, sporadic hemiplegic migraine, migraine with brainstem aura, retinal migraine, recurrent migraine and chronic migraine.

6. The use according to any one of claims 1and 5, wherein the medicament eliminates, reduces the severity of, and/or reduces the frequency of occurrence of at least one symptom of tension-type headaches or migraine, which symptom preferably includes at least one of (moderate to severe) headaches, and associated symptoms including aura, blurred vision, nausea, vomiting, delirium, nasal stuffiness, diarrhea, tinnitus, polyuria, pallor, sweating, localized edema of the scalp or face, scalp tenderness, prominence of a vein or artery in the temple, stiffness and tenderness of the neck, impairment of concentration and mood, cold and moist feeling in appendages, and sensitivity to light, sound, or smell.

7. The use according to any one of claims 1,, 5 and 6, wherein an additional active agent selected from the group consisting of a preventive migraine medication, an analgesic, a triptan and an ergotamine is to be further administered.

8. The use according to any one of claims 1 – 7, wherein the total daily dose that is to be administered is in the range of5 to 2000 mg, preferably 20 to 800 mg, more preferably the total daily dose is in the range of between 30 to 400 mg and most preferably the total daily dose is in the range of 150 to 250 mg.

9. The use according to any one of claims 1 – 8, wherein the medicament is to be administered orally, wherein, preferably, the medicament is to be administered in a solid form or in a liquid form, wherein more preferably the compound is admixed with an aqueous solution prior to administration, wherein even more preferably the aqueous solution is an isotonic aqueous solution and wherein most preferably the isotonic aqueous solution is saline.

10. The use according to any one of claims 1 – 9, wherein the medicament is to be administered at least twice daily, preferably wherein the medicament is to be administered twice daily, wherein more preferably the medicament is to be administered twice daily in two similar or equal doses.

11. The use according to claim 10, wherein the interval between two administrations is at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 hours.

12. The use according to any one of claims 1 – 11, wherein the subject to be treated is a primate.

13. The use according to claim 12, wherein the subject is a human.

14. The use according to claim 13, wherein the subject is a patient suffering from a mitochondrial disease.